As Plain as the Nose on Your Face: The Case for A Nasal (Mucosal) Route of Vaccine Administration for Covid-19 Disease Prevention.
作者信息
Travis Craig R
机构信息
Immugen Pharma LLC, South Miami, FL, United States.
出版信息
Front Immunol. 2020 Sep 30;11:591897. doi: 10.3389/fimmu.2020.591897. eCollection 2020.
Abstract
摘要
相似文献
1
As Plain as the Nose on Your Face: The Case for A Nasal (Mucosal) Route of Vaccine Administration for Covid-19 Disease Prevention.显而易见：采用鼻腔（黏膜）途径接种疫苗预防新冠疾病的理由
Front Immunol. 2020 Sep 30;11:591897. doi: 10.3389/fimmu.2020.591897. eCollection 2020.
2
Rapid COVID-19 vaccine development.新冠疫苗的快速研发。
Science. 2020 May 29;368(6494):945-946. doi: 10.1126/science.abb8923. Epub 2020 May 8.
3
The Race to Develop a COVID-19 Vaccine.新冠疫苗研发竞赛。
Am J Nurs. 2020 Oct;120(10):14-15. doi: 10.1097/01.NAJ.0000718556.85319.00.
4
Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development.在严重急性呼吸综合征冠状病毒2疫苗研发中平衡权宜性与科学严谨性
J Infect Dis. 2020 Jun 29;222(2):180-182. doi: 10.1093/infdis/jiaa234.
5
COVID-19 vaccine design: the Janus face of immune enhancement.COVID-19 疫苗设计：免疫增强的两面性。
Nat Rev Immunol. 2020 Jun;20(6):347-348. doi: 10.1038/s41577-020-0323-4. Epub 2020 Apr 28.
6
Progress and Concept for COVID-19 Vaccine Development.新型冠状病毒肺炎疫苗研发进展与理念
Biotechnol J. 2020 Jun;15(6):e2000147. doi: 10.1002/biot.202000147. Epub 2020 May 7.
7
Rational Vaccine Design in the Time of COVID-19.新冠疫情时期的合理疫苗设计。
Cell Host Microbe. 2020 May 13;27(5):695-698. doi: 10.1016/j.chom.2020.04.022.
8
Advances in skin science enable the development of a COVID-19 vaccine.皮肤科学的进展推动了新冠疫苗的研发。
J Am Acad Dermatol. 2020 Oct;83(4):1226-1227. doi: 10.1016/j.jaad.2020.05.126. Epub 2020 May 30.
9
An Effective COVID-19 Vaccine Needs to Engage T Cells.一种有效的新冠疫苗需要激发T细胞。
Front Immunol. 2020 Sep 28;11:581807. doi: 10.3389/fimmu.2020.581807. eCollection 2020.
10
COVID-19 shot protects monkeys.新冠疫苗对猴子有保护作用。
Science. 2020 May 1;368(6490):456-457. doi: 10.1126/science.368.6490.456.
引用本文的文献
1
Antiviral Effects of Sinamaz®: Potentials for COVID-19 Management.西那马斯®的抗病毒作用：对新冠病毒病的治疗潜力
Tanaffos. 2024 Mar;23(3):217-219.
2
Intranasal spike and nucleoprotein fusion protein-based vaccine provides cross-protection and reduced transmission against SARS-CoV-2 variants.基于鼻内刺突蛋白和核蛋白融合蛋白的疫苗可提供针对新冠病毒变异株的交叉保护并减少传播。
NPJ Vaccines. 2025 Apr 18;10(1):75. doi: 10.1038/s41541-025-01123-y.
3
Antibody-dependent enhancement of coronaviruses.冠状病毒的抗体依赖性增强作用。
Int J Biol Sci. 2025 Feb 3;21(4):1686-1704. doi: 10.7150/ijbs.96112. eCollection 2025.
4
BCG administration promotes the long-term protection afforded by a single-dose intranasal adenovirus-based SARS-CoV-2 vaccine.卡介苗接种可增强单剂量鼻内腺病毒载体新冠疫苗提供的长期保护作用。
iScience. 2023 Aug 11;26(9):107612. doi: 10.1016/j.isci.2023.107612. eCollection 2023 Sep 15.
5
Recent advances in respiratory immunization: A focus on COVID-19 vaccines.呼吸免疫接种的最新进展：重点关注 COVID-19 疫苗。
J Control Release. 2023 Mar;355:655-674. doi: 10.1016/j.jconrel.2023.02.011. Epub 2023 Feb 17.
6
Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions.辉瑞-生物科技（BNT162b2）、莫德纳（mRNA-1273）COVID-19 mRNA 疫苗与过敏反应。
J Natl Med Assoc. 2022 Dec;114(6):601-612. doi: 10.1016/j.jnma.2022.08.003. Epub 2022 Oct 28.
7
Vaccines Against COVID-19: A Review.新型冠状病毒肺炎疫苗综述
Vaccines (Basel). 2022 Mar 10;10(3):414. doi: 10.3390/vaccines10030414.
8
Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine.口服弹状病毒疫苗增强非人类灵长类动物的 SARS-CoV-2 免疫力。
Vaccine. 2022 Apr 1;40(15):2342-2351. doi: 10.1016/j.vaccine.2021.12.063. Epub 2022 Jan 10.
9
COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges.COVID-19 鼻内疫苗：当前进展、优势、前景和挑战。
Hum Vaccin Immunother. 2022 Nov 30;18(5):2045853. doi: 10.1080/21645515.2022.2045853. Epub 2022 Mar 8.
10
The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity.新冠病毒谜题：解析新疾病实体的病理生理学和表型。
Lancet Respir Med. 2021 Jun;9(6):622-642. doi: 10.1016/S2213-2600(21)00218-6. Epub 2021 May 6.
本文引用的文献
1
Immunogenicity and Toxicity of Different Adjuvants Can Be Characterized by Profiling Lung Biomarker Genes After Nasal Immunization.不同佐剂的免疫原性和毒性可通过鼻腔免疫后肺部生物标志物基因的特征来描述。
Front Immunol. 2020 Sep 11;11:2171. doi: 10.3389/fimmu.2020.02171. eCollection 2020.
2
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.SARS-CoV-2 反应性 T 细胞在健康供体和 COVID-19 患者中的研究。
Nature. 2020 Nov;587(7833):270-274. doi: 10.1038/s41586-020-2598-9. Epub 2020 Jul 29.
3
Longitudinal analyses reveal immunological misfiring in severe COVID-19.纵向分析揭示了重症 COVID-19 中的免疫失调。
Nature. 2020 Aug;584(7821):463-469. doi: 10.1038/s41586-020-2588-y. Epub 2020 Jul 27.
4
Disappearance of antibodies to SARS-CoV-2 in a -COVID-19 patient after recovery.一名新冠康复患者体内新冠病毒抗体消失。
Clin Microbiol Infect. 2020 Dec;26(12):1703-1705. doi: 10.1016/j.cmi.2020.07.009. Epub 2020 Jul 9.
5
Pre-existing immunity to SARS-CoV-2: the knowns and unknowns.SARS-CoV-2 预先存在的免疫力：已知和未知。
Nat Rev Immunol. 2020 Aug;20(8):457-458. doi: 10.1038/s41577-020-0389-z.
6
Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection.与 SARS-CoV-2 感染相关的血管病变和凝血病。
Cells. 2020 Jun 30;9(7):1583. doi: 10.3390/cells9071583.
7
COVID-19 pneumonia: CD8 T and NK cells are decreased in number but compensatory increased in cytotoxic potential.COVID-19 肺炎：CD8 T 细胞和 NK 细胞数量减少，但细胞毒性潜能代偿性增加。
Clin Immunol. 2020 Sep;218:108516. doi: 10.1016/j.clim.2020.108516. Epub 2020 Jun 20.
8
A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies.在小鼠中建立的 SARS-CoV-2 感染模型证明了中和抗体的保护作用。
Cell. 2020 Aug 6;182(3):744-753.e4. doi: 10.1016/j.cell.2020.06.011. Epub 2020 Jun 10.
9
The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.病毒刺突蛋白的受体结合域是 SARS-CoV-2 患者体内抗体的免疫优势和高度特异性靶标。
Sci Immunol. 2020 Jun 11;5(48). doi: 10.1126/sciimmunol.abc8413.
10
SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract.SARS-CoV-2 反向遗传学揭示了呼吸道感染的可变梯度。
Cell. 2020 Jul 23;182(2):429-446.e14. doi: 10.1016/j.cell.2020.05.042. Epub 2020 May 27.
Zotero 插件